Related Experiment Videos
[Can clopidogrel be responsible for neutropenia?]
Fauzia Vendrametto1, Walter Pitscheider, Rainer Oberhollenzer
1U.O. di Cardiologia, A.O. S. Maria degliAngeli, Pordenone. fauzia.v@tiscalinet.it
Giornale Italiano Di Cardiologia (2006)
|March 15, 2006
Summary
This case study highlights clopidogrel-induced neutropenia in an elderly patient. Drug withdrawal rapidly restored normal neutrophil counts, suggesting a causal link.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Coronary intervention with stent implantation is a common procedure in elderly patients.
- Clopidogrel is a widely used antiplatelet medication following such procedures.
Observation:
- An 80-year-old female developed severe neutropenia 38 days after initiating clopidogrel therapy.
- Other potential causes of neutropenia were systematically excluded.
Findings:
- Neutropenia resolved rapidly within days of discontinuing clopidogrel.
- This suggests a direct drug-induced effect on neutrophil levels.
Implications:
- Clinicians should consider clopidogrel as a potential cause of neutropenia in patients presenting with low neutrophil counts.
- Awareness of this adverse effect is crucial for patient safety and timely management.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...